Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Ti...
July 30 2019 - 8:30AM
Atossa Genetics Inc. (Nasdaq:
ATOS), a
clinical-stage biopharmaceutical company developing novel
therapeutics and delivery methods for breast cancer and other
breast conditions, today announced the online launch of company CEO
Steven Quay’s Tedx UofW Talk, “How to Be Smart When You’re Dense:
Preventing Breast Cancer by 2030.”
In the Tedx UofW talk, Steven Quay, M.D., Ph.D., Atossa’s Chief
Executive Officer outlines the journey of Atossa Genetics in
identifying improved ways to identify women at high risk of breast
cancer, using mammography to identify dense breast tissue.
Dr. Quay also details his experience with triumph, failure and
perseverance while trying to prevent one of the world’s most common
diseases: breast cancer. He emphasizes the need for unshaken
efforts to solve such complex problems, and ways that he and his
team are doing so in breast cancer research.
The talk has been posted online at
https://www.youtube.com/watch?v=hK4PlbYE_5M&list=PLsRNoUx8w3rNCo4uCVXiNDFZLiKrIOQ1J&index=5
and can also be accessed via the company’s website at
www.atossagenetics.com.
“I am grateful for having had the opportunity to address our
approach to breast cancer as something that, like cervical cancer,
has the potential to be completely eradicated over time. It
was an honor to participate in this University of Washington
program and I hope the information provided helps those who
participated in the event, as well as those who view it online,”
commented Dr. Quay.
Steven Quay is the founder of Seattle-based Atossa Genetics,
Inc., dedicated to breast cancer prevention. He received a Ph.D. in
Biological Chemistry and a M.D. from the University of Michigan, a
postdoc at MIT and Harvard, and he was a faculty member at Stanford
Medical School. His contributions to medicine, cancer, and
biochemistry have been cited more than 9,300 times, putting him in
the top 1% of the world’s scientists. Since entering the
biotech industry in 1983, he has founded six startups, invented
seven FDA-approved pharmaceuticals, and holds 87 U.S. patents.
Over 80 million people have benefited from the medicines he
invented. His current passion involves the prevention of the
two million yearly breast cancer cases worldwide. This talk
was given at a TEDx event using the TED conference format but
independently organized by a local community.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage biopharmaceutical
company developing novel therapeutics and delivery methods to treat
breast cancer and other breast conditions. For more
information, please visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
preliminary and final clinical results, actions and inactions by
the FDA, the outcome or timing of regulatory approvals needed by
Atossa including those needed to commence studies, lower than
anticipated rate of patient enrollment, estimated market size of
drugs under development, the safety and efficacy of Atossa's
products and services, performance of clinical research
organizations and investigators, obstacles resulting from
proprietary rights held by others with respect to fulvestrant, such
as patent rights, potential market sizes for Atossa's drugs under
development and other risks detailed from time to time in Atossa's
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics, Inc.Kyle GuseCFO and General Counsel(O)
866-893-4927kyle.guse@atossagenetics.com
Investor Relations Contact:
Scott GordonCoreIR377 Oak StreetConcourse 2Garden City, NY
11530Office: 516.222.2560scottg@CoreIR.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Sep 2023 to Sep 2024